| Name |
Valproic acid (USP);Depakene (TN) |
| Product |
|
| Generic |
VALPROIC (Actavis Pharma), VALPROIC (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (ANI Pharmaceuticals), VALPROIC ACID (ATLANTIC BIOLOGICALS CORP.), VALPROIC ACID (ATLANTIC BIOLOGICALS CORP.), VALPROIC ACID (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (Aphena Pharma Solutions - Tennessee), VALPROIC ACID (Bionpharma), VALPROIC ACID (Bryant Ranch Prepack), VALPROIC ACID (Bryant Ranch Prepack), VALPROIC ACID (Chartwell RX), VALPROIC ACID (Lannett Company), VALPROIC ACID (McKesson Corporation dba SKY Packaging), VALPROIC ACID (McKesson Corporation dba SKY Packaging), VALPROIC ACID (NCS HealthCare of KY), VALPROIC ACID (NorthStar Rx LLC), VALPROIC ACID (PAI Holdings), VALPROIC ACID (QUAGEN PHARMACEUTICALS LLC), VALPROIC ACID (REMEDYREPACK), VALPROIC ACID (REMEDYREPACK), VALPROIC ACID (REMEDYREPACK), VALPROIC ACID (Upsher-Smith Laboratories) |
| Formula |
C8H16O2 |
| Exact mass |
144.1150 |
| Mol weight |
144.21 |
| Structure |
 |
| Simcomp |
|
| Class |
Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blockerNeuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic |
| Remark |
Same as: C07185ATC code: N03AG01Chemical structure group: DG00849Product (DG00849): D00399 D00304<US> D00710<JP/US> |
| Efficacy |
Anticonvulsant |
| Comment |
Fatty acid derivativeValproic acid is contraindicated in patients with known urea cycle disorders [DS:H00164 H00185 H00186 H00187 H01028 H01032] |
| Target |
ABAT [HSA:18] [KO:K13524]SSADH [HSA:7915] [KO:K00139]GAD [HSA:2571 2572] [KO:K01580]CACNA1-T [HSA:8911 8912 8913] [KO:K04856 K04855 K04854] |
| Pathway |
hsa04020 Calcium signaling pathwayhsa04727 GABAergic synapse |
| Interaction |
|
| Structure map |
map07033 Anticonvulsantsmap07036 Calcium channel blocking drugsmap07048 Antimigraines |
| Other map |
map00982 Drug metabolism - cytochrome P450 |
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N03 ANTIEPILEPTICS N03A ANTIEPILEPTICS N03AG Fatty acid derivatives N03AG01 Valproic acid D00399 Valproic acid (USP) USP drug classification [BR:br08302] Anticonvulsants Anticonvulsants, Other Valproic Acid D00399 Valproic acid (USP) Antimigraine Agents Antimigraine Agents, Other Valproic Acid D00399 Valproic acid (USP) Bipolar Agents Mood Stabilizers Valproic Acid D00399 Valproic acid (USP)Drug groups [BR:br08330] Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blocker DG00849 Valproic acid D00399 Valproic acid Neuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic DG00849 Valproic acid D00399 Valproic acidDrug classes [BR:br08332] Neuropsychiatric agent DG03199 Antiepileptic agent D00399 Valproic acidTarget-based classification of drugs [BR:br08310] Ion channels Voltage-gated ion channels Calcium channels CACNA1-T D00399 Valproic acid (USP) Enzymes Oxidoreductases (EC1) Dehydrogenases SSADH D00399 Valproic acid (USP) Transferases (EC2) Aminotransferase ABAT D00399 Valproic acid (USP) Lyases (EC4) Carboxy-lyases GAD D00399 Valproic acid (USP) Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D00399Drug groups [BR:br08330] Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blocker DG00849 Valproic acid Neuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic DG00849 Valproic acid |
| Other DBs |
CAS: 99-66-1PubChem: 7847465ChEBI: 39867PDB-CCD: 2PP[PDBj] LigandBox: D00399NIKKAJI: J4.972G |
| LinkDB |
|
| KCF data |
ATOM 10 1 C1c C 25.4573 -18.6784 2 C1b C 25.4573 -17.3002 3 C1b C 24.2485 -19.3967 4 C6a C 26.6604 -19.3967 5 C1b C 24.2427 -16.5935 6 C1b C 23.0396 -18.6784 7 O6a O 26.6604 -20.7925 8 O6a O 27.8692 -18.6784 9 C1a C 23.0339 -17.3002 10 C1a C 21.8367 -19.3967BOND 9 1 1 2 1 2 1 3 1 3 1 4 1 4 2 5 1 5 3 6 1 6 4 7 1 7 4 8 2 8 5 9 1 9 6 10 1 |
